I want to end this week with an ASCO follow up and talking about something new. I must say that the sector is doing modestly better than I had feared and seems to have gotten its legs. This obviously does not mean that it is going to run but at least it does not seem […]
June 6 Biotech Update
I am back from ASCO with a lot to cover and I will focus on broader themes today and spend the rest of the week with more company specific commentary. The reaction to ASCO so far has been bad but as I noted before that is not completely unexpected. The trading action before ASCO does […]
January 9 Biotech Update
I am getting ready to head out to JPM but I wanted to have a quick JPM note this morning. In general, the news has been a little slow as compared to expectations but certainly bullish. I will highlight a couple of the more important stories. 1. We have almost $6B in deals in one […]
April 18 Biotech Update
There is a recurring theme with excitement to end the week but no merger Monday. I continue to believe we are still too early for there to be a pick-up in M&A but it is coming later in the year. We are starting to get AACR data and it will be interesting to see how […]
LOXO: Staying On TRK
Loxo Oncology presented highly anticipated results from its ongoing Phase 1 study of TRK inhibitor LOXO-101 yesterday November 8, in a latebreaker at AACR-NCI-EORTC; they did not disappoint. Disclosure of a response from just one patient with diagnosed TRK fusion mutation in a July publication of Cancer Discovery set much of this excitement in motion. […]
Loxo Oncology: One to Watch
Loxo Oncology (LOXO) is a biotech company built around the idea that cancer is best treated with highly targeted drugs paired to companion diagnostics. CEO Josh Bilenker, a partner at Aisling Capital, founded the company in 2013. Research and Development is outsourced, allowing about a dozen employees to manage company operations. Loxo acquired essentially all […]
